Skip to main
CELU

Celularity (CELU) Stock Forecast & Price Target

Celularity (CELU) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Celularity Inc’s focus on developing innovative placental-derived cell therapies positions it favorably within the biotechnology sector, particularly as it targets a range of indications, including cancer and degenerative diseases. The demonstrated efficacy of its product PDA-002, which shows competitive ulcer closure rates compared to existing FDA-approved therapies, underscores the company's potential for significant impact in the wound healing market. Additionally, the bio-banking segment's contribution to the majority of revenues highlights a stable revenue stream that supports the company's ongoing clinical development efforts.

Bears say

Celularity Inc faces significant challenges that could negatively impact its clinical trials and overall business operations, as manufacturing or other failures are likely to affect both the biobanking and degenerative disease segments. Additionally, the decline in natural killer (NK) cell function with age may hinder the effectiveness of their therapies, due to reduced cytokine secretion and decreased target cell cytotoxicity, which could limit market potential. Overall, these operational and biological challenges could substantially undermine investor confidence and adversely affect the company's financial health.

Celularity (CELU) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Celularity and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Celularity (CELU) Forecast

Analysts have given Celularity (CELU) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Celularity (CELU) has a Strong Buy consensus rating as of Jan 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Celularity (CELU)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.